Welcome to our dedicated page for Alumis SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. reported strong Phase 3 results for envudeucitinib, its oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. In the ONWARD1 and ONWARD2 trials, high levels of skin clearance were achieved and deepened through 24 weeks, with meaningful quality-of-life and itch improvements emerging early.
By Week 24, PASI 90 skin clearance rates reached 68.0% and 62.1%, and PASI 100 complete clearance reached 41.0% and 39.5% in envudeucitinib-treated patients. Safety and tolerability were favorable and consistent with Phase 2 data, with mostly mild, manageable side effects and no new safety signals reported.
More than 1,700 adults were enrolled across the parallel Phase 3 trials, which also showed rapid improvement in difficult-to-treat scalp psoriasis. Alumis plans to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in the second half of 2026 and is running an ONWARD3 long-term extension and the LUMUS Phase 2b trial in systemic lupus erythematosus, with topline LUMUS data expected in the third quarter of 2026.
Alumis Inc. files a shelf registration statement to permit future offerings of multiple security types. The filing registers an indeterminate number of common stock, preferred stock, debt securities and warrants under a base prospectus and a $300.0 million sales agreement with Cantor Fitzgerald & Co. dated March 18, 2026, permitting sales of voting common stock from time to time after effectiveness.
The base prospectus covers various mechanisms and convertible issuance paths; specific terms, amounts, offering prices and proceeds treatment will be disclosed in future prospectus supplements.
Alumis Inc. files its annual report describing a fast-advancing immunology pipeline and a transformative acquisition. The company focuses on targeted therapies that modulate TYK2 and other immune pathways to treat psoriasis, lupus and neuroinflammatory diseases.
Lead candidate envudeucitinib (envu) delivered positive Phase 3 psoriasis results, with about 74% of patients achieving PASI 75 and 65% achieving PASI 90 at Week 24, and was generally well tolerated. Alumis plans to submit an NDA for envu in psoriasis in the second half of 2026 and is running a global Phase 2b trial in systemic lupus erythematosus. A CNS-penetrant TYK2 inhibitor, A-005, showed favorable Phase 1 safety, and the ACELYRIN merger added lonigutamab for thyroid eye disease and net assets valued at $426.0 million in a stock transaction valued at approximately $238.1 million.
Alumis Inc. reported full-year 2025 results and major pipeline progress. Total revenue reached $24,050 thousand, driven by license and collaboration revenue, compared with no revenue in 2024. Operating expenses rose to $477,854 thousand, mainly from higher research and development and general and administrative costs.
Net loss narrowed to $243,325 thousand from $294,233 thousand, helped by a $187,907 thousand gain on bargain purchase and higher interest income. At December 31, 2025, Alumis held $89,670 thousand in cash and cash equivalents and $218,831 thousand in marketable securities.
The company highlighted positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis and plans to submit an NDA in 2H 2026. Potentially pivotal Phase 2b topline data in systemic lupus erythematosus are anticipated in 3Q 2026. Alumis also completed an upsized public offering in January 2026, raising $345,1 million in gross proceeds.
Alumis Inc. reported that Chief Legal Officer Sanam Pangali received a stock option grant for 186,200 shares of common stock at an exercise price of $26.31 per share on January 26, 2026. These options give the right to buy Alumis shares at that price in the future.
According to the vesting terms, 25% of the shares underlying the option vest on January 26, 2027. The remaining shares then vest in equal monthly installments over the following 36 months, as long as the executive maintains Continuous Service under the company’s 2024 Equity Incentive Plan, with potential acceleration as provided in the plan.
Alumis Inc. reported that President, CEO and Chairman Martin Babler received a new stock option grant. On January 26, 2026, he was awarded an option to buy 745,875 shares of Alumis common stock at an exercise price of $26.31 per share, expiring January 25, 2036.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares then vest in equal monthly installments over the following 36 months, contingent on his continuous service to Alumis and subject to possible acceleration under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported a stock option grant to Chief Business & Strategy Officer Roy C. Hardiman. On January 26, 2026, he was awarded a stock option covering 190,875 shares of common stock at an exercise price of $26.31 per share.
According to the filing, 25% of the shares underlying this option vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. The option expires on January 25, 2036, and all 190,875 derivative securities are reported as directly owned.
Alumis Inc. reported that Chief Development Officer Bradley Mark Christopher received a stock option grant on January 26, 2026. The option covers 190,225 shares of common stock at an exercise price of $26.31 per share and is held directly.
According to the vesting terms, 25% of the shares underlying the option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continuous service under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported that Chief Medical Officer Jorn Drappa received a new stock option grant. The option covers 221,450 shares of common stock at an exercise price of $26.31 per share, awarded on January 26, 2026.
According to the vesting terms, 25% of the shares vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Drappa’s continuous service under the company’s 2024 Equity Incentive Plan and subject to potential acceleration provisions.
Alumis Inc. (ALMS) reported an equity award to its Chief Financial Officer, John R. Schroer. On January 26, 2026, he was granted a stock option covering 202,225 shares of common stock at an exercise price of $26.31 per share.
These options vest over time: 25% of the underlying shares vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to Alumis under the company’s 2024 Equity Incentive Plan.